• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Okay, who decided that we shouldn't do Cardiovascular outcome studies?

Anonymous

Guest
We've known forever that this was the price of admission into the diabetes market. Whats the deal?

Who made the decision and when do we get to see their head on a plate?

Moses? Who?
 

<



We've known forever that this was the price of admission into the diabetes market. Whats the deal?

Who made the decision and when do we get to see their head on a plate?

Moses? Who?

Probably it's because they were afraid that the studies would confirm what the FDA saw in the meta analysis. NNI was banking on the same deal as Victoza - REMS and a pledge to conduct post marketing CV studies.

Kudos to the FDA for placing patient safety ahead of corporate profit.